Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Therapeutic monoclonal antibody interference in electrophoretic and immunofixation techniques (CROSBI ID 715328)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Šahinović, Ines ; Sinčić-Petričević, Jasminka ; Oršić-Frič, Vlasta ; Borzan, Vladimir ; Pavela, Jasna ; Fijačko, Mirjana ; Šerić, Vatroslav Therapeutic monoclonal antibody interference in electrophoretic and immunofixation techniques // Clinica chimica acta. 2019. str. 1-784 doi: 10.1016/j.cca.2019.03.104

Podaci o odgovornosti

Šahinović, Ines ; Sinčić-Petričević, Jasminka ; Oršić-Frič, Vlasta ; Borzan, Vladimir ; Pavela, Jasna ; Fijačko, Mirjana ; Šerić, Vatroslav

engleski

Therapeutic monoclonal antibody interference in electrophoretic and immunofixation techniques

Background-aim Therapeutic monoclonal antibodies (t-mAb) have rapidly become a clinically important drug class because of their immunomodulatory effects. Serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) are ordered for a number of indications, including immunodeficiences, autoimmune and infectious diseases, for which treatment with a t-mAb is becoming common. These laboratory tests are also important in diagnostic work-up of patients with suspected plasma cell dyscrasias. Majority of t-mAb are of IgG kappa isotype, what raises a concern whether a t-mAb, if not properly identified, could be misinterpreted on SPE or IFE. The aim of our study was to determine if t-mAbs infliximab, adalimumab, vedolizumab and rituximab interfere with SPE or IFE. Methods Serum samples from four patients undergoing therapy with infliximab (IFX), adalimumab (ADA), vedolizumab (VEDO) and rituximab (RITU) were used. Two samples of venous blood were collected for each patient at peak (a day after drug administration-IFX, ADA and VEDO and after a drug administration on day 5 of therapy protocol-RITU) and at trough (a day before next dose administration). SPE analysis was performed using Sebia Minicap capillary electrophoresis (Sebia, USA) and IFE using Sebia Hydrasys (Sebia, USA). Results SPE and IFE findings show no abnormalities for IFX and ADA at peak concentration. No abnormalities were identified on SPE nor IFE for any of the t- mAb at trough concentration. On SPE only for rituximab a band was visible at the cathodal end of the gamma fraction. On IFE monoclonal bands identified as IgG kappa were noted for VEDO and RITU. VEDO migrated closer to the middle of the gamma fraction, although not as a clear sharp band. RITU migrated to the far cathodal end of gamma fraction. Conclusions Our results show that awareness of the presence of monoclonal protein by SPE/IFE following recent VEDO or RITU administration is important to avoid clinical misinterpretation and unnecessary further evaluation for pathologic monoclonal gammapathy. When SPE and IFE are performed within a couple of days from infusion, especially for VEDO and RITU, t-mAb can appear as a monoclonal protein. SPE/IFU should be conducted a day prior to the drug administration in order to avoid misinterpretation.

Therapeutic monoclonal antibody ; interference ; electrophoresis ; immunofixation

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

1-784.

2019.

nije evidentirano

objavljeno

10.1016/j.cca.2019.03.104

Podaci o matičnoj publikaciji

Clinica chimica acta

Elsevier

0009-8981

1873-3492

Podaci o skupu

23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB 2019)

poster

19.05.2019-23.05.2019

Barcelona, Španjolska

Povezanost rada

Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Kliničke medicinske znanosti

Poveznice
Indeksiranost